参考文献/References:
[1]李良,吴瑞锋,刘子滕,等.多西他赛+顺铂新辅助化疗联合手术治疗非小细胞肺癌临床疗效及对相关肿瘤标记物的影响[J].实用医院临床杂志,2017,14(3):35-38.[2]王先毅,何周杰.培美曲塞与多西他赛联合顺铂治疗晚期非小细胞肺癌临床疗效的对比研究[J].实用心脑肺血管病杂志,2017,25(4):155-157.[3]刘哲,程亮亮,于显凤.术前GP新辅助化疗对局部晚期非小细胞肺癌手术患者预后的影响[J].解放军医药杂志,2019,31(6):25-28.[4]倪明立,谢玲,秦贝贝.Wnt/β-catenin信号通路在非小细胞肺癌组织的表达及意义[J].广东医学,2016,37(15):2299-2301.[5]非小细胞肺癌辅助治疗胸外科共识专家组.非小细胞肺癌术后辅助治疗中国胸外科专家共识(2018版)[J].中国肺癌杂志,2018,21(10):731-737.[6]李晓雷,徐俊,胡欣,等.多中心多学科治疗模式下对局部晚期非小细胞肺癌患者的新辅助化疗疗效及预后影响的临床研究[J].东南大学学报(医学版),2018,37(4):667-672.[7]赵月鸣,董莹,郝杰,等.EGFR-TKIs靶向治疗对老年晚期非小细胞肺癌患者外周血淋巴细胞亚群及近远期疗效的影响[J].中国老年学杂志,2019,39(23):5692-5694.[8]唐小慧,王娟娟,唐鸣,等.IMRT联合同步化疗对老年非小细胞肺癌患者T淋巴细胞亚群及循环肿瘤细胞的影响[J].广西医科大学学报,2019,36(4):598-601.[9]蒋友慧.新辅助化疗前后血清血管内皮生长因子水平的变化[J].中国普外基础与临床杂志,2016,23(3):345-345.[10]庞一雄,黄维江,胡磊,等.小细胞肺癌恶性程度与新辅助化疗预后的研究[J].海南医学院学报,2016,22(9):898-901.[11]徐晓鸿,陈家斌,夏银稳,等.沙利度胺联合吉非替尼新辅助化疗对非小细胞肺癌的临床价值[J].昆明医科大学学报,2016,37(1):65-68.[12]范宜楚,汪笑冬,迟明友,等.术前新辅助化疗对局限期小细胞肺癌预后的影响研究[J].中国全科医学,2016,19(14):1653-1658.[13]Zhang Z,Gasser RB,Yang X,et al.Two benzimidazole resistance -associated SNPs in the isotype-1 β-tubulingene predominate in Haemonchus contortus populations from eight regions in China[J].Int J Parasitol Drugs Drug Resist,2016,6(3):199-206.[14]牛朝霞,李宁宁,梁芳,等.紫杉醇化疗联合参一胶囊对晚期非小细胞肺癌患者的疗效及安全性[J].世界中医药,2016,11(7):1265-1267,1271.[15]Chan SK,Hagen HR,Swanson SA,et al.Development of Bipotent Cardiac/Skeletal Myogenic Progenitors from MESP1+Mesoderm[J].Stem Cell Reports,2016,6(1):26-34.[16]梁秋萍,殷俊.EGFR TKI+TP方案及TP方案对晚期非小细胞肺癌治疗临床效果及肿瘤标志物水平的影响[J].成都医学院学报,2016,11(1):40-44.[17]仇建玲.培美曲塞联合铂类化疗方案在非小细胞肺癌患者中的疗效分析[J].中外医学研究,2016,14(5):145-146.[18]张飔雪.新辅助化疗对局部晚期非小细胞肺癌患者临床疗效和手术切除率的影响[J].实用癌症杂志,2016,31(8):1299-1301.[19]巫云立,黄菁,张勇,等.多西他赛联合不同铂类在晚期非小细胞肺癌一线治疗中的效果分析[J].中外医学研究,2016,14(12):36-37.[20]张旭宇,李冬雷,马少林.新辅助化疗治疗晚期非小细胞肺癌的临床研究[J].中西医结合心血管病电子杂志,2020,35(8):61-62.
相似文献/References:
[1]田 亮,郭 楠,苗志刚,等.非小细胞肺癌中ZEB1和FoxO3a表达及意义[J].医学信息,2018,31(03):16.[doi:10.3969/j.issn.1006-1959.2018.03.006]
TIAN Liang,GUO Nan,MIAO Zhi-gang,et al.Expression and Significance of ZEB1 and FoxO3a in Non-small Cell Lung Cancer[J].Medical Information,2018,31(23):16.[doi:10.3969/j.issn.1006-1959.2018.03.006]
[2]陶 洪,孙国平.非小细胞肺癌根治术后复发及进展影响因素的回顾性分析[J].医学信息,2018,31(12):61.[doi:10.3969/j.issn.1006-1959.2018.12.019]
TAO Hong,SUN Guo-ping.Retrospective Analysis of Factors Influencing Recurrence and Progression after Radical Resection of Non-small Cell Lung Cancer[J].Medical Information,2018,31(23):61.[doi:10.3969/j.issn.1006-1959.2018.12.019]
[3]朱淑娟.多西他赛在控制晚期非小细胞肺癌恶性胸腔积液的
疗效和安全性评估[J].医学信息,2018,31(15):132.[doi:10.3969/j.issn.1006-1959.2018.15.042]
ZHU Shu-juan.Efficacy and Safety of Docetaxel in the Control of Malignant Pleural Effusion in Patients with Advanced Non-small Cell Lung Cancer[J].Medical Information,2018,31(23):132.[doi:10.3969/j.issn.1006-1959.2018.15.042]
[4]李春磊,裴艳志,邹志田,等.非小细胞肺癌组织中趋化因子受体CCR7的
表达及其临床意义[J].医学信息,2018,31(17):14.[doi:10.3969/j.issn.1006-1959.2018.17.004]
LI Chun-lei,PEI Yan-zhi,ZOU Zhi-tian,et al.Expression of Chemokine Receptor CCR7 in Non-small Cell Lung Cancer and its Clinical Significance[J].Medical Information,2018,31(23):14.[doi:10.3969/j.issn.1006-1959.2018.17.004]
[5]杨 莉.TP方案联合回生口服液治疗中晚期非小细胞肺癌的疗效观察[J].医学信息,2018,31(17):17.[doi:10.3969/j.issn.1006-1959.2018.17.005]
YANG Li.Therapeutic Effect of TP Regimen Combined with Huisheng Oral Liquid in the Treatment of Advanced Non-small Cell Lung Carcinoma[J].Medical Information,2018,31(23):17.[doi:10.3969/j.issn.1006-1959.2018.17.005]
[6]吴森林,高 斌.中性粒细胞/淋巴细胞比值与介入治疗中晚期非小细胞肺癌患者预后的相关性[J].医学信息,2019,32(03):82.[doi:10.3969/j.issn.1006-1959.2019.03.025]
WU Sen-lin,GAO Bin.Correlation between Neutrophil/Lymphocyte Ratio and Prognosis in Patients with Advanced Non-small Cell Lung Cancer[J].Medical Information,2019,32(23):82.[doi:10.3969/j.issn.1006-1959.2019.03.025]
[7]田春琴,赵新汉,蒋冬梅,等.二线用药EGFR-TKIs治疗非选择型NSCLC疗效的Meta分析[J].医学信息,2018,31(20):49.[doi:10.3969/j.issn.1006-1959.2018.20.015]
TIAN Chun-qin,ZHAO Xin-han,JIANG Dong-mei,et al.Meta-analysis of the Efficacy of Second-line EGFR-TKIs in the Treatment of Nonselective NSCLC[J].Medical Information,2018,31(23):49.[doi:10.3969/j.issn.1006-1959.2018.20.015]
[8]张晓玲.替吉奥联合多西他赛治疗转移性乳腺癌的临床疗效观察[J].医学信息,2018,31(20):128.[doi:10.3969/j.issn.1006-1959.2018.20.038]
ZHANG Xiao-ling.Clinical Observation of Tegafur,Gimeracil and Oteracil Porassium Capsules Combined with Docetaxel in the Treatment of Metastatic Breast Cancer[J].Medical Information,2018,31(23):128.[doi:10.3969/j.issn.1006-1959.2018.20.038]
[9]徐闻霞,陆红艳,黄 斌.胸腔镜肺叶切除和肺段切除治疗ⅠA期非小细胞肺癌的疗效比较[J].医学信息,2018,31(21):100.[doi:10.3969/j.issn.1006-1959.2018.21.027]
XU Wen-xia,LU Hong-yan,HUANG Bin.Comparison of Thoracoscopic Lobectomy and Segmentectomy for ⅠA Non-small Cell Lung Cancer[J].Medical Information,2018,31(23):100.[doi:10.3969/j.issn.1006-1959.2018.21.027]
[10]付红星,冯小剑,彭文苗,等.康艾注射液联合化疗治疗晚期非小细胞肺癌的临床研究[J].医学信息,2018,31(24):115.[doi:10.3969/j.issn.1006-1959.2018.24.033]
FU Hong-xing,FENG Xiao-jian,PENG Wen-miao,et al.Clinical Study of Kang'ai Injection Combined with Chemotherapy in the Treatment of Advanced Non-small Cell Lung Cancer[J].Medical Information,2018,31(23):115.[doi:10.3969/j.issn.1006-1959.2018.24.033]